Suppr超能文献

血管抑肽与组织转谷氨酰胺酶的相互作用。

The interaction of angiocidin with tissue transglutaminase.

机构信息

Temple University, Department of Neuroscience, Center for Neurovirology, MERB-7th Floor, 3500 N. Broad Street, Philadelphia, PA 19140, USA.

出版信息

Exp Mol Pathol. 2010 Feb;88(1):15-25. doi: 10.1016/j.yexmp.2009.11.001. Epub 2009 Nov 18.

Abstract

Angiocidin, a matrix bound and tumor associated protein, has been shown to inhibit tumor progression and angiogenesis. We previously demonstrated that angiocidin binds to thrombospondin-1 and alpha2beta1 integrin. We now show that angiocidin binds and is a preferred substrate for tissue transglutaminase-2 (tTgase). Angiocidin bound tTgase saturably with a Kd of 26 nM, while an angiocidin deletion mutant missing the matrix binding domain of angiocidin failed to bind tTgase. tTgase colocalized with angiocidin on endothelial cells. tTgase bound anti-angiocidin immunoprecipitates of endothelial cell lysates. Breast cancer cells expressing high levels of tTgase attached to angiocidin immobilized on tissue culture plates. Angiocidin was a preferred substrate for tTgase forming high molecular weight cross-linked multimers when treated with tTgase. Cross-linked angiocidin contained iso-peptide bonds as demonstrated by Western blotting and immunohistochemical colocalization studies using endothelial cells treated with angiocidin. Cross-linked angiocidin inhibited cell migration in contrast to monomeric angiocidin and inhibited localization of fibronectin (FN), a pro-tumorigenic matrix protein, into the extracellular matrix (ECM) of tumor and HUVE cells. Our studies provide an additional explanation for the anti-tumor activity of angiocidin suggesting that cross-linked angiocidin disrupts the tumor ECM making it less permissive for tumor growth.

摘要

血管抑素是一种结合在基质上的肿瘤相关蛋白,已被证明能抑制肿瘤的进展和血管生成。我们之前的研究表明,血管抑素与血小板反应蛋白-1 和α2β1 整合素结合。我们现在发现血管抑素结合并作为组织转谷氨酰胺酶-2(tTgase)的首选底物。血管抑素与 tTgase 结合呈饱和状态,Kd 值为 26 nM,而缺失血管抑素基质结合域的血管抑素缺失突变体则不能与 tTgase 结合。tTgase 与内皮细胞上的血管抑素共定位。tTgase 结合内皮细胞裂解物中抗血管抑素免疫沉淀物。表达高水平 tTgase 的乳腺癌细胞附着在固定在组织培养板上的血管抑素上。当用 tTgase 处理时,血管抑素是 tTgase 的首选底物,形成高分子量的交联多聚体。交联的血管抑素含有同肽键,如用内皮细胞处理后进行 Western blot 和免疫组化共定位研究所示。交联的血管抑素抑制细胞迁移,与单体血管抑素相反,并抑制纤维连接蛋白(FN),一种促肿瘤基质蛋白,定位到肿瘤和 HUVE 细胞的细胞外基质(ECM)中。我们的研究为血管抑素的抗肿瘤活性提供了另一种解释,表明交联的血管抑素破坏了肿瘤 ECM,使其对肿瘤生长的容忍度降低。

相似文献

1
The interaction of angiocidin with tissue transglutaminase.
Exp Mol Pathol. 2010 Feb;88(1):15-25. doi: 10.1016/j.yexmp.2009.11.001. Epub 2009 Nov 18.
2
Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein.
Exp Cell Res. 2006 Aug 1;312(13):2443-53. doi: 10.1016/j.yexcr.2006.04.009. Epub 2006 Apr 30.
5
Tissue transglutaminase as a modifying enzyme of the extracellular matrix in PVR membranes.
Invest Ophthalmol Vis Sci. 2003 Jan;44(1):355-64. doi: 10.1167/iovs.02-0224.
7
Cloning and characterization of angiocidin, a tumor cell binding protein for thrombospondin-1.
J Cell Biochem. 2004 May 1;92(1):125-46. doi: 10.1002/jcb.20076.
8
Potential role of tissue transglutaminase in glaucoma filtering surgery.
Invest Ophthalmol Vis Sci. 2006 Sep;47(9):3835-45. doi: 10.1167/iovs.05-0960.
9
A novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis.
Cell Death Dis. 2013 Sep 19;4(9):e808. doi: 10.1038/cddis.2013.318.

引用本文的文献

2
Reduction of angiocidin contributes to decreased HepG2 cell proliferation.
Afr Health Sci. 2013 Sep;13(3):560-4. doi: 10.4314/ahs.v13i3.5.
3
Cellular functions of tissue transglutaminase.
Int Rev Cell Mol Biol. 2012;294:1-97. doi: 10.1016/B978-0-12-394305-7.00001-X.
4
Extracellular TG2: emerging functions and regulation.
FEBS J. 2011 Dec;278(24):4704-16. doi: 10.1111/j.1742-4658.2011.08346.x. Epub 2011 Nov 21.

本文引用的文献

1
The immunomodulatory role of angiocidin, a novel angiogenesis inhibitor.
Curr Pharm Des. 2009;15(17):1937-48. doi: 10.2174/138161209788453149.
3
The novel angiogenic inhibitor, angiocidin, induces differentiation of monocytes to macrophages.
Cancer Res. 2008 Jul 15;68(14):5905-14. doi: 10.1158/0008-5472.CAN-07-6179.
4
Biological and therapeutic significance of tissue transglutaminase in pancreatic cancer.
Amino Acids. 2009 Apr;36(4):709-16. doi: 10.1007/s00726-008-0128-4. Epub 2008 Jul 2.
5
Tissue transglutaminase-mediated chemoresistance in cancer cells.
Drug Resist Updat. 2007 Aug-Oct;10(4-5):144-51. doi: 10.1016/j.drup.2007.06.002. Epub 2007 Jul 27.
6
Transglutaminase 2 inhibitors and their therapeutic role in disease states.
Pharmacol Ther. 2007 Aug;115(2):232-45. doi: 10.1016/j.pharmthera.2007.05.003. Epub 2007 May 13.
7
Clinical significance of serum angiocidin levels in hepatocellular carcinoma.
Cancer Lett. 2007 Jun 18;251(1):28-35. doi: 10.1016/j.canlet.2006.10.023. Epub 2006 Dec 22.
8
Roles of transglutaminases in cardiac and vascular diseases.
Front Biosci. 2007 Jan 1;12:2530-45. doi: 10.2741/2253.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验